Hypoxia Sensing and Responses in Parkinson's Disease

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Feb 10

PMID 38339038

Authors

Johannes Burtscher

Yves Duderstadt

Hannes Gatterer

Martin Burtscher

Roman Vozdek

Gregoire P Millet

Andrew A Hicks

Hannelore Ehrenreich

Martin Kopp

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is associated with various deficits in sensing and responding to reductions in oxygen availability (hypoxia). Here we summarize the evidence pointing to a central role of hypoxia in PD, discuss the relation of hypoxia and oxygen dependence with pathological hallmarks of PD, including mitochondrial dysfunction, dopaminergic vulnerability, and alpha-synuclein-related pathology, and highlight the link with cellular and systemic oxygen sensing. We describe cases suggesting that hypoxia may trigger Parkinsonian symptoms but also emphasize that the endogenous systems that protect from hypoxia can be harnessed to protect from PD. Finally, we provide examples of preclinical and clinical research substantiating this potential.

Citing Articles

Hypoxia Pathways in Parkinson's Disease: From Pathogenesis to Therapeutic Targets.

Gao Y, Zhang J, Tang T, Liu Z Int J Mol Sci. 2024; 25(19).

PMID: 39408813 PMC: 11477385. DOI: 10.3390/ijms251910484.

Spiral volumetric optoacoustic tomography of reduced oxygen saturation in the spinal cord of M83 mouse model of Parkinson's disease.

Combes B, Kalva S, Benveniste P, Tournant A, Law M, Newton J Eur J Nucl Med Mol Imaging. 2024; 52(2):427-443.

PMID: 39382580 PMC: 11732882. DOI: 10.1007/s00259-024-06938-w.

New Aspects Regarding the Fluorescence Spectra of Melanin and Neuromelanin in Pigmented Human Tissue Concerning Hypoxia.

Leupold D, Buder S, Pfeifer L, Szyc L, Riederer P, Strobel S Int J Mol Sci. 2024; 25(15).

PMID: 39126026 PMC: 11313424. DOI: 10.3390/ijms25158457.

References

Lohmann S, Grigoletto J, Bernis M, Pesch V, Ma L, Reithofer S . Ischemic stroke causes Parkinson's disease-like pathology and symptoms in transgenic mice overexpressing alpha-synuclein. Acta Neuropathol Commun. 2022; 10(1):26. PMC: 8867857. DOI: 10.1186/s40478-022-01327-6. View

Chen T, Li J, Chao D, Sandhu H, Liao X, Zhao J . δ-Opioid receptor activation reduces α-synuclein overexpression and oligomer formation induced by MPP(+) and/or hypoxia. Exp Neurol. 2014; 255:127-36. DOI: 10.1016/j.expneurol.2014.02.022. View

Ast T, Wang H, Marutani E, Nagashima F, Malhotra R, Ichinose F . Continuous, but not intermittent, regimens of hypoxia prevent and reverse ataxia in a murine model of Friedreich's ataxia. Hum Mol Genet. 2023; 32(16):2600-2610. PMC: 10407700. DOI: 10.1093/hmg/ddad091. View

Jin W . Regulation of BDNF-TrkB Signaling and Potential Therapeutic Strategies for Parkinson's Disease. J Clin Med. 2020; 9(1). PMC: 7019526. DOI: 10.3390/jcm9010257. View

Devos D, Hirsch E, Wyse R . Seven Solutions for Neuroprotection in Parkinson's Disease. Mov Disord. 2020; 36(2):306-316. DOI: 10.1002/mds.28379. View

Schnell P, Ignacak M, Bauer A, Striet J, Paulding W, Czyzyk-Krzeska M . Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors. J Neurochem. 2003; 85(2):483-91. DOI: 10.1046/j.1471-4159.2003.01696.x. View

Leston Pinilla L, Ugun-Klusek A, Rutella S, De Girolamo L . Hypoxia Signaling in Parkinson's Disease: There Is Use in Asking "What HIF?". Biology (Basel). 2021; 10(8). PMC: 8389254. DOI: 10.3390/biology10080723. View

Vogtel M, Michels A . Role of intermittent hypoxia in the treatment of bronchial asthma and chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol. 2010; 10(3):206-13. DOI: 10.1097/ACI.0b013e32833903a6. View

Wakhloo D, Scharkowski F, Curto Y, Butt U, Bansal V, Steixner-Kumar A . Functional hypoxia drives neuroplasticity and neurogenesis via brain erythropoietin. Nat Commun. 2020; 11(1):1313. PMC: 7062779. DOI: 10.1038/s41467-020-15041-1. View

10.

Brigadski T, Lessmann V . The physiology of regulated BDNF release. Cell Tissue Res. 2020; 382(1):15-45. PMC: 7529619. DOI: 10.1007/s00441-020-03253-2. View

11.

Griffin H, Pugh K, Kumar P, Balanos G . Long-term facilitation of ventilation following acute continuous hypoxia in awake humans during sustained hypercapnia. J Physiol. 2012; 590(20):5151-65. PMC: 3497569. DOI: 10.1113/jphysiol.2012.236109. View

12.

Surmeier D, Obeso J, Halliday G . Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci. 2017; 18(2):101-113. PMC: 5564322. DOI: 10.1038/nrn.2016.178. View

13.

Mohammadi A, Amooeian V, Rashidi E . Dysfunction in Brain-Derived Neurotrophic Factor Signaling Pathway and Susceptibility to Schizophrenia, Parkinson's and Alzheimer's Diseases. Curr Gene Ther. 2018; 18(1):45-63. DOI: 10.2174/1566523218666180302163029. View

14.

Leander Johansen J, Sager T, Lotharius J, Witten L, Mork A, Egebjerg J . HIF prolyl hydroxylase inhibition increases cell viability and potentiates dopamine release in dopaminergic cells. J Neurochem. 2010; 115(1):209-19. DOI: 10.1111/j.1471-4159.2010.06917.x. View

15.

Whone A . Monoclonal Antibody Therapy in Parkinson's Disease - The End?. N Engl J Med. 2022; 387(5):466-467. DOI: 10.1056/NEJMe2207681. View

16.

Espay A, Morgante F, Merola A, Fasano A, Marsili L, Fox S . Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. Ann Neurol. 2018; 84(6):797-811. DOI: 10.1002/ana.25364. View

17.

Pang S, Ho P, Liu H, Leung C, Li L, Chang E . The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson's disease. Transl Neurodegener. 2019; 8:23. PMC: 6696688. DOI: 10.1186/s40035-019-0165-9. View

18.

Yu S, Liu X, Li Y, Lu G, Chen B . [Effect of repeated acute hypoxic treatment on the expression of alpha-synuclein in the mouse brain cortex]. Sheng Li Xue Bao. 2004; 56(2):263-8. View

19.

Raberin A, Burtscher J, Burtscher M, Millet G . Hypoxia and the Aging Cardiovascular System. Aging Dis. 2023; 14(6):2051-2070. PMC: 10676797. DOI: 10.14336/AD.2023.0424. View

20.

Haider T, Casucci G, Linser T, Faulhaber M, Gatterer H, Ott G . Interval hypoxic training improves autonomic cardiovascular and respiratory control in patients with mild chronic obstructive pulmonary disease. J Hypertens. 2009; 27(8):1648-54. DOI: 10.1097/HJH.0b013e32832c0018. View